Lupin acquires Renascience Pharma to bolster UK portfolio

Lupin Limited (BSE: LUPIN) announced today that its wholly-owned subsidiary, Lupin Healthcare (UK) Limited, has acquired Renascience Pharma Limited, a UK-based pharmaceutical company. The acquisition, completed April 2, 2025, grants Lupin ownership of Renascience, which will operate as its subsidiary. Renascience is a licensee and sole supplier of four niche Bio-Generics products to the primary and secondary care market in the UK with no local generics competition. The financial details of RPL as on February 29, 2025, are as follows: Turnover of GBP 3.51 million and Net Worth of GBP 0.95 million. The consideration for 100% of the shareholding was GBP 12.3 million. Renascience portfolio includes injectable cephalosporines, a topical treatment for ear pain, and a branded quinazoline-like diuretic, serving cardiology and nephrology indications.